Developing an inhibitor starts with the synthesis of compounds that can bind to the target molecule. These compounds are screened for activity against the target in vitro. Promising candidates undergo further preclinical testing, including studies on efficacy, toxicity, and pharmacokinetics. Successful compounds then progress to clinical trials, where they are tested in humans to evaluate safety and therapeutic efficacy.
